Results
thyroid deficiency
MAY
The study enrolled patients from May 2019 to March 2020. A total of 155 patients were randomised to one of 3 treatment groups: 51 to test arm A; 53 to test arm B; and 51 to control arm C. All randomised patients received at least 1 dose of the assigned study drug and therefore the safety population comprised of 155 patients. However, 10 of these patients either withdrew consent or were not available for at least one post-baseline assessment. Thus the ITT population consisted of 145 patients. Of these, 90 patients were able to meet the commitment for a physical follow-up visit within the permitted visit window at the end of 12 weeks of treatment (despite pandemic-related restrictions) and fulfil other eligibility criteria for the PP analysis. Baseline demographics is shown in Table 
Demographics of Analysed Study PopulationsOf the 55 patients who had to be excluded from the PP population, 44 were not able to honour the trial visit schedule due to pandemic-related restrictions and were unavailable for the crucial 3Treatment groups were apparently comparable for demographics, pre-existing illnesses, and concomitant medication at baseline other than 4 and 2 patients with a history of thyroid deficiency and related medication in test groups A and B against none in the control group. Further, there were no apparent differences in baseline scores for any of the endpoints assessed for the study. No statistical tests were performed to assess baseline comparability of treatment groups [